Optimal postnatal corticosteroid regimens to prevent bronchopulmonary dysplasia with minimal adverse effects

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Pharmacology

Background:

• Postnatal corticosteroids are frequently used for extremely preterm infants to prevent or treat bronchopulmonary dysplasia (BPD).
• Current clinical practice lacks clear guidelines regarding optimal timing, dosage, type, route, and indications for corticosteroid use in BPD.
• Early dexamethasone administration in the first week of life is linked to adverse neurodevelopmental outcomes.

Purpose of the Study:

• To review the current evidence on the use of postnatal corticosteroids in preterm infants with BPD.
• To highlight the complexities and uncertainties surrounding corticosteroid therapy for BPD.
• To emphasize the need for individualized, risk-based decision-making in corticosteroid administration.

Main Methods:

• Systematic review of existing literature on postnatal corticosteroid use in BPD.
• Analysis of studies comparing different corticosteroid types (dexamethasone, hydrocortisone) and administration routes (systemic, inhaled, intratracheal).
• Evaluation of evidence regarding timing, dosage, and neurodevelopmental outcomes.

Main Results:

• Early systemic dexamethasone is not recommended due to neurodevelopmental risks.
• Dexamethasone may benefit high-risk infants for cerebral palsy-free survival but harm low-risk infants.
• Optimal dosing and long-term safety data for various administration routes (inhaled, intratracheal) remain limited or inconclusive.

Conclusions:

• Postnatal corticosteroids should be used cautiously and selectively in ventilator-dependent infants with severe BPD.
• Individualized risk assessment is crucial for guiding corticosteroid therapy.
• Further high-quality trials are necessary to determine optimal strategies and long-term safety, particularly concerning neurodevelopmental outcomes.